Himachal Pradesh News
Himachal Pradesh High Court Flags ‘Unsafe Drugs’: Notices Issued to Central & State Authorities
In a significant development raising concerns over public health safety, the Himachal Pradesh High Court has taken suo motu cognisance of alleged unsafe pharmaceutical products being manufactured in the state’s industrial belt.
In a significant development raising concerns over public health safety, the Himachal Pradesh High Court has taken suo motu cognisance of alleged unsafe pharmaceutical products being manufactured in the state’s industrial belt.
The court has issued notices to key regulatory authorities, including the Drug Controller General of India (DCGI), the Central Drugs Standard Control Organisation (CDSCO), and the Ministry of Health and Family Welfare, seeking urgent responses on the matter.
26 Drugs Under Scanner, 19 Pharma Firms Named
The issue came to light following a communication received by the office of the Chief Justice, which flagged 26 drugs manufactured by 19 pharmaceutical companies. These drugs, produced in major industrial zones like Baddi, Solan, Paonta Sahib, and Kangra, are suspected to pose risks to public health and safety.
Taking the matter seriously, a Division Bench led by Chief Justice Gurmeet Singh Sandhawalia and Justice Bipin Chander Negi also referred to media reports highlighting similar concerns, further strengthening the case for immediate scrutiny.
Court Seeks Accountability and Stronger Regulation
By issuing notices, the High Court has asked both state and central authorities to clarify:
- What steps have been taken to prevent the manufacture and distribution of these flagged drugs
- How existing drug safety and quality control mechanisms are being enforced
- Whether there have been regulatory lapses in monitoring pharmaceutical units
The move signals the court’s intent to ensure strict accountability and reinforce public trust in India’s pharmaceutical sector.
Public Health at Stake
Himachal Pradesh, particularly regions like Baddi, is known as a major pharmaceutical manufacturing hub. Any compromise in drug quality not only affects local consumers but can also have nationwide and global implications.
This case highlights a pressing need for robust oversight, transparency, and strict compliance with safety standards to prevent potential health risks.
Read Also : BJP Plans Statewide Campaign Against Congress Ahead of Himachal Pradesh Urban Polls 2026